![conference banner](/images/conference-banner.jpeg)
Abstract
Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.
Keywords: Chemotherapy, immunotherapy, management, radiotherapy, small cell lung cancer, target therapies.
Current Drug Targets
Title:Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Volume: 18 Issue: 3
Author(s): Giuseppe Lo Russo, Marianna Macerelli, Marco Platania, Nicoletta Zilembo, Milena Vitali, Diego Signorelli, Claudia Proto, Monica Ganzinelli, Rosaria Gallucci, Francesco Agustoni, Gianpiero Fasola, Filippo de Braud and Marina Chiara Garassino
Affiliation:
Keywords: Chemotherapy, immunotherapy, management, radiotherapy, small cell lung cancer, target therapies.
Abstract: Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.
Export Options
About this article
Cite this article as:
Russo Lo Giuseppe, Macerelli Marianna, Platania Marco, Zilembo Nicoletta, Vitali Milena, Signorelli Diego, Proto Claudia, Ganzinelli Monica, Gallucci Rosaria, Agustoni Francesco, Fasola Gianpiero, Braud de Filippo and Garassino Chiara Marina, Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450117666160502152331
DOI https://dx.doi.org/10.2174/1389450117666160502152331 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular and Thermodynamic Studies on DNA Triplex Formed in the Promoter Region of HMGB1 Gene as a Selective Target for Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Anticancer Evaluation of Novel Quinazolinone Acetamides: Synthesis and Characterization
Anti-Cancer Agents in Medicinal Chemistry Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer using Curcumin Encapsulated Vesicular Drug Delivery Systems
Current Pharmaceutical Design Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade
Current Medicinal Chemistry Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Review on Paclitaxel Derivatization: Enhanced Anticancer Action
Letters in Drug Design & Discovery AGAP2-AS1: An Indispensable lncRNA in Tumors
Mini-Reviews in Medicinal Chemistry Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Metal Containing Chloroquinolines: Beyond Hit and Miss Antimalarial Efficacy to Solid Science
Mini-Reviews in Medicinal Chemistry Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Tricyclic Antidepressants-loaded Biodegradable PLGA Nanoparticles: In Vitro Characterization and In Vivo Analgesic and Anti-Allodynic Effect
Current Nanoscience microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Meet Our Editorial Board Member
Letters in Drug Design & Discovery Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy